Law360 (March 3, 2008, 12:00 AM EST) -- In a 4-4 split, the U.S. Supreme Court has affirmed a lower court's ruling in a battle between Pfizer Inc.'s Warner-Lambert unit and a group of Michigan patients, effectively allowing the Michigan residents to advance their claims against Pfizer over the diabetes drug Rezulin.
Handing down a two-sentence decision just one week after oral arguments, the justices did little to resolve a conflict between lower courts over whether the U.S. Food and Drug Administration's regulations shield a pharmaceutical company from consumers' claims that the company defrauded the FDA during the drug approval process.
“It makes things at least as clear as...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!